BioSpace News Archive

Rallybio Corporation today announced its participation in the following upcoming investor conferences,

Serimmune will discuss its Serum Epitope Repertoire Analysis (SERA) platform and how it can be applied in various studies to gain insight into past and present humoral immune responses in individuals and cohorts.

Fusion Pharmaceuticals Inc. today announced that the Company will participate in two upcoming investor conferences.

Aurion Biotech announced it has been selected as “Regenerative Therapeutics Company of the Year” in the third annual BioTech Breakthrough Awards program conducted by BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products and services around the globe.

Biomerica, Inc., a global provider of advanced medical products announced that several new Gastrointestinal groups have signed up and begun using the Company’s revolutionary inFoods® IBS Product.

Eagle Pharmaceuticals, Inc. today announced that the Company will release its third quarter 2023 financial results on Thursday, November 9, 2023, before the market opens.

Cullinan Oncology, Inc. (Nasdaq: CGEM; “Cullinan”) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today reported on recent and upcoming business highlights and announced its financial results for the third quarter ended September 30, 2023.

Algernon Pharmaceuticals Inc. is pleased to announce that it has received a Notice of Allowance from the Japanese Patent Office for patent application No. 2021-512244 entitled “Compositions and Methods for Treating Non-Alcoholic Steatohepatitis” with NP-251 (Repirinast).

Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced financial results for the third quarter ended September 30, 2023.

PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today provided a corporate update and reported financial results for the three and nine months ended September 30, 2023.